# Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

> **NCT00591266** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 566 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Azilsartan Medoxomil and amlodipine
- **DRUG:** Azilsartan Medoxomil and amlodipine
- **DRUG:** Amlodipine

## Key facts

- **NCT ID:** NCT00591266
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-04
- **Target enrollment:** 566 (ACTUAL)
- **Last updated:** 2011-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00591266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00591266, "Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00591266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*